Mangoceuticals, Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on April 23, 2024, will not undergo review. The SEC's communication, dated April 30, 2024, was addressed to Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. For further inquiries, the SEC has provided contact information for Juan Grana, a staff member in the Division of Corporation Finance, Office of Industrial Applications and Services.

Mangoceuticals, Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on April 23, 2024, will not undergo review. The SEC's communication, dated April 30, 2024, was addressed to Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. For further inquiries, the SEC has provided contact information for Juan Grana, a staff member in the Division of Corporation Finance, Office of Industrial Applications and Services.